These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 9442546)

  • 21. [Obsessive-compulsive disorder, frontostriatal system and the effect of the serotonergic system].
    Baving L; Schmidt MH
    Z Kinder Jugendpsychiatr Psychother; 2000 Feb; 28(1):35-44. PubMed ID: 10746297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors.
    Maina G; Albert U; Salvi V; Bogetto F
    J Clin Psychiatry; 2004 Oct; 65(10):1365-71. PubMed ID: 15491240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography.
    Suhara T; Takano A; Sudo Y; Ichimiya T; Inoue M; Yasuno F; Ikoma Y; Okubo Y
    Arch Gen Psychiatry; 2003 Apr; 60(4):386-91. PubMed ID: 12695316
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis.
    Greist JH; Jefferson JW; Kobak KA; Katzelnick DJ; Serlin RC
    Arch Gen Psychiatry; 1995 Jan; 52(1):53-60. PubMed ID: 7811162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data.
    Szegedi A; Wetzel H; Leal M; Härtter S; Hiemke C
    J Clin Psychiatry; 1996 Jun; 57(6):257-64. PubMed ID: 8666564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions.
    Goodman WK; Ward H; Kablinger A; Murphy T
    J Clin Psychiatry; 1997; 58 Suppl 5():32-49. PubMed ID: 9184625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic therapy of obsessive compulsive disorder.
    DeVeaugh-Geiss J
    Adv Pharmacol; 1994; 30():35-52. PubMed ID: 7833296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.
    Landeros-Weisenberger A; Bloch MH; Kelmendi B; Wegner R; Nudel J; Dombrowski P; Pittenger C; Krystal JH; Goodman WK; Leckman JF; Coric V
    J Affect Disord; 2010 Feb; 121(1-2):175-9. PubMed ID: 19577308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.
    Askari N; Moin M; Sanati M; Tajdini M; Hosseini SM; Modabbernia A; Najand B; Salimi S; Tabrizi M; Ashrafi M; Hajiaghaee R; Akhondzadeh S
    CNS Drugs; 2012 Oct; 26(10):883-92. PubMed ID: 22873680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder.
    López-Ibor JJ; Saiz J; Cottraux J; Note I; Viñas R; Bourgeois M; Hernández M; Gómez-Pérez JC
    Eur Neuropsychopharmacol; 1996 May; 6(2):111-8. PubMed ID: 8791036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder.
    Zitterl W; Aigner M; Stompe T; Zitterl-Eglseer K; Gutierrez-Lobos K; Wenzel T; Zettinig G; Hornik K; Pirker W; Thau K
    Neuropsychopharmacology; 2008 Dec; 33(13):3126-34. PubMed ID: 18354388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The platelet benzodiazepine receptor is unaltered in obsessive-compulsive disorder.
    Weizman R; Hermesh H; Karp L; Dar DE; Munitz H; Gavish M
    Clin Neuropharmacol; 1993 Jun; 16(3):211-5. PubMed ID: 8389247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology.
    Zohar J; Insel TR
    Biol Psychiatry; 1987 Jun; 22(6):667-87. PubMed ID: 3036259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum cholesterol in patients with obsessive compulsive disorder during treatment with behavior therapy and SSRI or placebo.
    Peter H; Tabrizian S; Hand I
    Int J Psychiatry Med; 2000; 30(1):27-39. PubMed ID: 10900559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.
    Figgitt DP; McClellan KJ
    Drugs; 2000 Oct; 60(4):925-54. PubMed ID: 11085201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.
    Barr LC; Goodman WK; Anand A; McDougle CJ; Price LH
    Am J Psychiatry; 1997 Sep; 154(9):1293-5. PubMed ID: 9286191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacotherapy of obsessive-compulsive disorder.
    McDougle CJ; Goodman WK; Price LH
    Pharmacopsychiatry; 1993 May; 26 Suppl 1():24-9. PubMed ID: 8378419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical predictors of drug response in obsessive-compulsive disorder.
    Erzegovesi S; Cavallini MC; Cavedini P; Diaferia G; Locatelli M; Bellodi L
    J Clin Psychopharmacol; 2001 Oct; 21(5):488-92. PubMed ID: 11593074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Citalopram for treatment-resistant obsessive-compulsive disorder.
    Pallanti S; Quercioli L; Paiva RS; Koran LM
    Eur Psychiatry; 1999 Apr; 14(2):101-6. PubMed ID: 10572334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder.
    Flament MF; Rapoport JL; Murphy DL; Berg CJ; Lake CR
    Arch Gen Psychiatry; 1987 Mar; 44(3):219-25. PubMed ID: 3548637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.